Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620553 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HPGD | |
| SCHEMBL12460960 | 0.80 | NPC1 (0.84) | RAB9ANPC1SMN1; SMN2AHRMEN1 | |
| SCHEMBL24599379 | 0.79 | PSEN1 (0.47) | NPC1ALDH1A1MAPTGAAHPGD | |
| SCHEMBL3580813 | 0.78 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2AHRMEN1 | |
| SCHEMBL12464176 | 0.77 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2AHRMEN1 | |
| SCHEMBL3590753 | 0.76 | LMNA (0.64) | RAB9ANPC1SMN1; SMN2AHRMEN1 | |
| SCHEMBL2753548 | 0.75 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2AHRMEN1 | |
| SCHEMBL2174374 | 0.73 | LCK (0.52) | ALDH1A1 | |
| SCHEMBL17632138 | 0.71 | ALDH1A1 (0.44) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10719011 | 0.71 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2AHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004216-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCF1 | RAB9A 2028/4885NPC1 23/4885SMN1; SMN2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.